Bo Li1,2, Shuo Shen1, Siting You3, Guoxiao Zhang1, Suizhi Gao1, Xiaohan Shi1, Huan Wang1, Xiaoyi Yin1, Xiongfei Xu1, Shiwei Guo4, Gang Jin5. 1. Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital Affiliated to Navy Medical University (Second Military Medical University), 168 Changhai Road, Shanghai, 200433, China. 2. Department of General Surgery, Beidaihe Rehabilitation and Recuperation Center of Joint Logistics Support Force, 4 Xihaitan Road, Qinhuangdao, 066100, China. 3. Central laboratory, Changhai Hospital Affiliated to Navy Medical University (Second Military Medical University), 168 Changhai Road, Shanghai, 200433, China. 4. Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital Affiliated to Navy Medical University (Second Military Medical University), 168 Changhai Road, Shanghai, 200433, China. gestwa@163.com. 5. Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital Affiliated to Navy Medical University (Second Military Medical University), 168 Changhai Road, Shanghai, 200433, China. jingang@smmu.edu.cn.
Abstract
PURPOSE: The study aimed to investigate the potential benefit of more than 4 courses of S1 adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC) after surgery. METHOD: Data were retrospectively collected from consecutive patients who underwent S-1 adjuvant chemotherapy following curative pancreatectomy between January 2016 and December 2018. Four-courses and > 4 courses cohorts were compared for overall survival (OS) as a primary outcome, and relapse-free survival (RFS) and adverse event incidence as secondary outcomes. RESULTS: Four-courses and > 4 courses cohorts comprised 99 patients and 64 ones, respectively. TNM stage (stage II vs. I: HR, 2.125; 95% CI, 1.164-4.213; P = 0.015), duration of S-1 administration (4 vs. > 4 courses: HR, 3.113; 95% CI, 1.531-6.327; P = 0.002) and tumor grade (G3 vs. G1/2: HR, 3.887; 95% CI, 1.922-7.861; P < 0.001) were independent prognostic factors. Under the condition of patients' survival time beyond 8 months, the OS of patients in > 4 courses cohort was significantly prolonged compared with that of 4 courses cohort (4 vs. > 4 courses: HR, 2.284; 95% CI, 1.197-4.358; P = 0.012), especially for patients in TNM stageII (4 vs. > 4 courses: HR, 2.906; 95% CI, 1.275-6.623; P = 0.011).RFS and adverse events incidence did not signifcantly difer between both cohorts. CONCLUSION: Prolonged duration of S-1 intake is beneficial to prognosis of patients with PDAC resection.
PURPOSE: The study aimed to investigate the potential benefit of more than 4 courses of S1 adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC) after surgery. METHOD: Data were retrospectively collected from consecutive patients who underwent S-1 adjuvant chemotherapy following curative pancreatectomy between January 2016 and December 2018. Four-courses and > 4 courses cohorts were compared for overall survival (OS) as a primary outcome, and relapse-free survival (RFS) and adverse event incidence as secondary outcomes. RESULTS: Four-courses and > 4 courses cohorts comprised 99 patients and 64 ones, respectively. TNM stage (stage II vs. I: HR, 2.125; 95% CI, 1.164-4.213; P = 0.015), duration of S-1 administration (4 vs. > 4 courses: HR, 3.113; 95% CI, 1.531-6.327; P = 0.002) and tumor grade (G3 vs. G1/2: HR, 3.887; 95% CI, 1.922-7.861; P < 0.001) were independent prognostic factors. Under the condition of patients' survival time beyond 8 months, the OS of patients in > 4 courses cohort was significantly prolonged compared with that of 4 courses cohort (4 vs. > 4 courses: HR, 2.284; 95% CI, 1.197-4.358; P = 0.012), especially for patients in TNM stageII (4 vs. > 4 courses: HR, 2.906; 95% CI, 1.275-6.623; P = 0.011).RFS and adverse events incidence did not signifcantly difer between both cohorts. CONCLUSION: Prolonged duration of S-1 intake is beneficial to prognosis of patients with PDAC resection.
Authors: Hitomi Sakamoto; Marc A Attiyeh; Jeffrey M Gerold; Alvin P Makohon-Moore; Akimasa Hayashi; Jungeui Hong; Rajya Kappagantula; Lance Zhang; Jerry P Melchor; Johannes G Reiter; Alexander Heyde; Craig M Bielski; Alexander V Penson; Mithat Gönen; Debyani Chakravarty; Eileen M O'Reilly; Laura D Wood; Ralph H Hruban; Martin A Nowak; Nicholas D Socci; Barry S Taylor; Christine A Iacobuzio-Donahue Journal: Cancer Discov Date: 2020-03-19 Impact factor: 38.272